Overview
BCRX market data
Price History
BCRX price chart
Valuation & Profitability
- P/E (TTM)
- 9.56 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.21 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.56 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -40.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.00 – $11.22 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.5B · P/B 13.88 · P/S 2.68.
Company News
RBC Capital Maintains Outperform on BioCryst Pharma, Lowers Price Target to $13Benzinga · Aug 6, 2026, 5:07 PM
Wedbush Maintains Outperform on BioCryst Pharma, Lowers Price Target to $20Benzinga · Aug 6, 2026, 3:49 PM
BioCryst Pharma shares are trading higher after the company reported better-than-expected Q2 sales results.Benzinga · Aug 5, 2026, 11:58 AM
BioCryst Pharma Affirms FY2026 Sales Guidance of $635.000M-$660.000M vs $666.201M EstBenzinga · Aug 5, 2026, 11:05 AM
BioCryst Pharma Q2 EPS $0.30, Sales $218.250M Beat $182.514M EstimateBenzinga · Aug 5, 2026, 11:04 AM
8-K/A filing — BIOCRYST PHARMACEUTICALS INC (BCRX)SEC EDGAR · Aug 4, 2026, 11:01 AM
JP Morgan Reinstates Neutral on BioCryst Pharma, Announces $12 Price TargetBenzinga · Jul 13, 2026, 11:06 AM
RBC Capital Maintains Outperform on BioCryst Pharma, Raises Price Target to $14Benzinga · Jul 7, 2026, 3:40 PM
HC Wainwright & Co. Maintains Buy on BioCryst Pharma, Maintains $32 Price TargetBenzinga · Jun 30, 2026, 2:40 PM
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga · Jun 30, 2026, 1:10 PM